Navigation Links
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Date:4/21/2009

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8 (a transmembrane cation channel protein) in cancer cells and induce cell death. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 in patients with solid tumors that are refractory to standard therapies.

The Phase 1 trial will enroll three to six patients per cohort during the dose escalation phase of the study. An expansion cohort may be enrolled following determination of the maximum tolerated dose. The primary endpoint of the study will be safety, but patients also will be evaluated for anti-tumor activity as well as tolerance of the drug in order to determine the optimal schedule and level of dosing. The trial has been initiated at South Texas Accelerated Research Therapeutics (START) in San Antonio Texas under the direction of Dr. Anthony W. Tolcher.

"D3263 is a drug candidate that has potential applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "The ability of D3263 to inhibit growth of TRPM8 expressing tumors in preclinical studies coupled with its oral bioavailability make it an appealing product candidate to advance into human clinical trials."

Patients interested in additional information about this trial may visit www.clinicaltrials.gov and use the search term "D3263."

About TRPM8

TRPM8 (also known a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... Inc. (NASDAQ: CYBX ), a global leader in ... announced it will participate in the 33 rd  Annual ... San Francisco . Dan ... at 11:00 AM Pacific Time.  A live audio webcast of ... Relations link on the Cyberonics home page at www.cyberonics.com ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
(Date:12/26/2014)... Plugin and template developers from Pixel ... for Final Cut Pro X. , “TransPack Volume 5 gives ... pull off an industry professional look” Said Christina Austin, CEO ... TransPack Volume 5, a new level of professionalism will become ... over 50 Final Cut Pro X transitions featuring organic animations. ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... in Colorado,s metro, markets the Complete Picture ... Aug. 4 Anthem Blue Cross and Blue ... industry-leading transparency,initiative. Now, members in Colorado,s metro markets ... that provides total estimated costs,associated with all aspects ...
... Mo. Injuries are the leading cause of death ... to the Centers for Disease Control and Prevention. In ... that children living in households with unrelated adults are ... injuries, compared to children living with two biological parents. ...
... AYSO kids to Lead Soccer Community in Nationwide ... Fundraising Effort to Fight Malaria, NEW YORK, ... and the American Youth Soccer Organization,(AYSO) today announced the "More Than ... partnership is to raise funds and,awareness to help fight malaria and ...
... Minn., Aug. 4 Mayo Clinic,s,medical experts offer breadth ... Olympic Games and Olympians. These are just some of ... meet your needs., Michael Joyner, M.D., is an ... track and field. He says that athletes,performances continue to ...
... ... Expansion Efforts, SAN FRANCISCO, Aug. 4 Quantros, ... healthcare,industry, today announced a series of activities for support of alternative,Web ... are being implemented to ensure those using a browser,other than market ...
... and medication review ... program, ... Stores has officially introduced the Prescription,Rewards Club, a discount drug and personal ... their suppliers, Sav-Mor has responded to competitors, $4,generic drug programs by going ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 2Health News:Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado 3Health News:Risk of unintentional injury death is high for young children living with unrelated adults 2Health News:FC Barcelona & FCB Foundation, Malaria No More and AYSO Launch Initiative to 'Kick it to Malaria' 2Health News:FC Barcelona & FCB Foundation, Malaria No More and AYSO Launch Initiative to 'Kick it to Malaria' 3Health News:Mayo Clinic Experts Offer Insights on Olympians 2Health News:Mayo Clinic Experts Offer Insights on Olympians 3Health News:Quantros Expanding Support for Alternative Web Browsers 2Health News:Quantros Expanding Support for Alternative Web Browsers 3Health News:Michigan-based Company Introduces Discount Prescription Drug Program 2
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: